RE:RE:RE: IV OV+ICI sequential administration in clinical trials Using a dual administration approach with ONCY's pelareorep involving intravenous delivery + intratumoral injection is being explored, however the most effective approach that is currently being employed is IV pelareorep + IV immune checkpoint inhibitor, both for effectivenss and the convenience of delivery.
Over time I would expect that both ONCY's pelareorep + immune checkpoint inhibitor could be delivered SQ - but that will be up to ONCY's acquirer to advance sometime in their future clinical development plans. IMO.